Mental health · Chicago area, IL
Mental health studies in Chicago area, IL
68 recruiting studies have a site in the Chicago area. This page includes nearby cities such as Evanston, Oak Brook, Oak Lawn, Park Ridge.
68 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.
- Location
- Naperville, IL + 46 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Chicago, IL + 33 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Janssen Research & Development, LLC
- Location
- Chicago, IL + 41 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Chicago, IL + 44 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Evanston, IL + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Tonix Pharmaceuticals, Inc.
- Location
- Chicago, IL + 25 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
Janssen Research & Development, LLC
- Location
- Skokie, IL + 6 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Vanda Pharmaceuticals
- Location
- Chicago, IL + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Reunion Neuroscience Inc
- Location
- Chicago, IL + 26 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 4
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Neurocrine Biosciences
- Location
- Naperville, IL + 18 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Device for Treating Generalized Anxiety
BTL Industries Ltd.
- Location
- Chicago, IL + 2 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 3
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
Transcend Therapeutics
- Location
- Chicago, IL + 36 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Brexanolone Lifting Outcomes Of Moms
Lipocine Inc.
- Location
- Chicago, IL + 15 other US sites
- Eligibility basics
- Ages 15–45 · Women only
- RecruitingPhase 3
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bristol-Myers Squibb
- Location
- Chicago, IL + 39 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
52-week Open Label Safety-Tolerability Study
LB Pharmaceuticals Inc.
- Location
- Chicago, IL + 22 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
Bristol-Myers Squibb
- Location
- Chicago, IL + 7 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc.
- Location
- Chicago, IL + 14 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
AbbVie
- Location
- Chicago, IL + 32 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
Novartis Pharmaceuticals
- Location
- Chicago, IL + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Syndeio Biosciences, Inc
- Location
- Chicago, IL + 22 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 3
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
LB Pharmaceuticals Inc.
- Location
- Chicago, IL + 12 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
LB Pharmaceuticals Inc.
- Location
- Chicago, IL + 25 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Bristol-Myers Squibb
- Location
- Chicago, IL + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
AbbVie
- Location
- Chicago, IL + 46 other US sites
- Eligibility basics
- Ages 18–65
Who these studies look for
Studies usually require a confirmed diagnosis and stable circumstances, and they monitor safety closely. If you are in crisis, contact a crisis line or emergency services rather than a study.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.